Let’s Talk… SMA at EPNS 2022 | Laurent Servais

Laurent Servais talks about the challenges in treatment decision making for spinal muscular atrophy and how they could be addressed, drawing on early-phase anti-myostatin antibody research as a potential treatment solution if shown to be beneficial in phase 3 trials.

Study identifies miRNAs upregulated in SMA

Emanuela Abiusi outlines the results of a study showing that certain microRNAs are upregulated in muscle biopsy and serum samples taken from people with spinal muscular atrophy, and discusses the potential of these microRNAs as a target for SMN-independent therapies (4:46).